EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Use of Biological Drugs in Patients with Chronic Dermatoses at Hospital Umum Sarawak: A 13-year Real-world Data

Hock Gin Teo, Siaw Ling Lai, Ingrid Pao Lin Ting, Yan Teo, Henrietta Albela, Min Moon Tang

Malaysian Journal of Dermatology · 2024

DOI: 10.4103/mjd.mjd_23_24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Malaysian Journal of Dermatology, 2024. Verfasst von Hock Gin Teo und 5 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

There has been a paradigm shift in the treatment of various chronic dermatoses using biological drugs. We aim to describe the characteristics of patients with chronic dermatoses who receive biological drugs. Materials and Methods: This was a retrospective study on the patients who received any form of biological drugs at the dermatology clinic between 2010 and July 2023. Medical records were retrieved and analyzed.

Results

A total of 78 patients received biological drugs for 13 years. The median age of the patients who first received the biological drugs was 39.6 years (range: 3–82). The biological drugs funding resources were from the hospital medication fund (45.2%), public servant fund (36.6%), and others. Psoriasis was the most common indication with a total of 62 (79.5%) patients, followed by atopic dermatitis ( n = 8, 10.3%), and chronic spontaneous urticaria ( n = 4, 5.1%). In our subanalysis of the use of biological drugs for 62 patients with psoriasis, the most frequently used agents were the interleukin 17 (IL-17) inhibitor secukinumab (39.0%) and anti-IL12/23 ustekinumab (26.0%). There were 33 (42.3%) patients who achieved meaningful with sustainable clinical response and were continued with the biological drugs longer than 12 months (range: 14–114 months). Thirteen patients switched to another biological drug mainly due to loss of efficacy. Twelve patients stopped completely mainly due to primary failure and adverse events. The most severe adverse events reported were tuberculosis and hepatitis B reactivation.

Conclusion

About 42.3% of patients had sustainable responses with the first biological drugs prescribed for more than a year.

Zitieren

APA

Teo, H. G., Lai, S. L., Ting, I. P. L., Teo, Y., Albela, H., & Tang, M. M. (2024). Use of Biological Drugs in Patients with Chronic Dermatoses at Hospital Umum Sarawak: A 13-year Real-world Data. Malaysian Journal of Dermatology. https://doi.org/10.4103/mjd.mjd_23_24

Vancouver

Teo HG, Lai SL, Ting IPL, Teo Y, Albela H, Tang MM. Use of Biological Drugs in Patients with Chronic Dermatoses at Hospital Umum Sarawak: A 13-year Real-world Data. Malaysian Journal of Dermatology. 2024. doi:10.4103/mjd.mjd_23_24

BibTeX
@article{Teo2024,
  author = {Teo, Hock Gin and Lai, Siaw Ling and Ting, Ingrid Pao Lin and Teo, Yan and Albela, Henrietta and Tang, Min Moon},
  title = {Use of Biological Drugs in Patients with Chronic Dermatoses at Hospital Umum Sarawak: A 13-year Real-world Data},
  journal = {Malaysian Journal of Dermatology},
  year = {2024},
  doi = {10.4103/mjd.mjd_23_24}
}
Kostenlos starten →